Add BrightSurf on Google Email

Mays Cancer Center: Targeting certain molecular interactions could yield new strategies for treating prostate cancer

Scientists at Mays Cancer Center found that altering androgen receptor multivalent interactions may lead to new treatments for prostate cancer. The study suggests that precise levels of these interactions are crucial for proper hormone-induced gene expression.

SourceUniversity of Texas Health Science Center at San Antonio·JournalMolecular Cell·TypeExperimental study·DateOct 5, 2023

High cure rate, low toxicity maintained with shortened radiation treatment for intermediate risk prostate cancer, study finds

A phase III trial suggests that fewer and higher doses of radiation therapy delivered over five sessions are as effective as lower doses delivered over several weeks for patients with locally advanced disease. The treatment achieved a 96% five-year disease control rate, comparable to 95% for conventional radiation.

Men who trust their doctors, receive adequate time and general information about prostate cancer screening are more likely to have productive discussions

A scoping review identified four key themes: everyday language, thorough information, adequate discussion time, and a trusting relationship. The study also highlighted the impact of racism on Black men's medical interactions. Researchers suggest strategies to support men's communication preferences.

SourceAmerican Academy of Family Physicians·JournalThe Annals of Family Medicine·DateSep 25, 2023

Personalized combination treatment turns on an immunometabolic switch to effectively control an aggressive form of prostate cancer

Researchers developed a personalized combination treatment that turned on an immunometabolic switch to effectively control aggressive prostate cancer. The treatment showed complete tumor control and long-lasting survival without side effects in a mouse model of advanced prostate cancer.

SourceUniversity of Chicago Medical Center·JournalClinical Cancer Research·DateSep 18, 2023

JNM publishes consensus statement on patient selection and appropriate use of Lu-177 PSMA-617 radionuclide therapy

The Society of Nuclear Medicine and Molecular Imaging has issued a new consensus statement to standardize the selection and management of patients with metastatic castrate-resistant prostate cancer (mCRPC) treated with Lu-177 PSMA radionuclide therapy. The statement recommends performing PSMA PET within three months of treatment or sin...

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateSep 5, 2023

A free online tool can help prostate cancer patients save on out-of-pocket drug costs

A free online tool can help prostate cancer patients save thousands of dollars in out-of-pocket drug costs by comparing Medicare Part D prescription plans. The Medicare Part D Plan Finder identifies significant savings for patients taking abiraterone or enzalutamide, two common prescription drugs for advanced prostate cancer.

SourceMichigan Medicine - University of Michigan·JournalUrology Practice·TypeData/statistical analysis·DateSep 5, 2023

CORRECTION: Outdoor air pollution may increase non-lung cancer risk in older adults

A Harvard T.H. Chan School of Public Health study found that chronic exposure to fine particulate air pollutants (PM2.5) and nitrogen dioxide (NO2) increases the risk of colorectal and prostate cancers in older adults. NO2 exposure was also associated with an increased risk of breast cancer, while PM2.5 exposure had mixed results.

SourceHarvard T.H. Chan School of Public Health·JournalEnvironmental Epidemiology·TypeObservational study·DateAug 11, 2023

A multiplex assay to assess activated p300/CBP in circulating prostate tumor cells

A new multiplex assay has been developed to assess activated p300/CBP in circulating prostate tumor cells, revealing correlations with clinical outcomes and potential therapeutic targets for castration-resistant prostate cancer. The study found that patients with upregulated p300/CBP activity had shorter response times to ARSI therapy.

SourceImpact Journals LLC·JournalOncotarget·TypeExperimental study·DateJul 24, 2023

Diversity plays a key role in Black Americans trust of videos about prostate cancer

A new study published in JAMA Network Open found that Black Americans are more likely to trust videos about prostate cancer presented by a Black doctor. The study, led by researchers at NYU Grossman School of Medicine, involved over 2,900 participants and showed that racial diversity among healthcare providers is crucial for improving ...

SourceNYU Langone Health / NYU Grossman School of Medicine·JournalJAMA Network Open·TypeRandomized controlled/clinical trial·DateJul 19, 2023

EMBARGOED: In preclinical study, Sylvester researchers target treatment-resistant prostate cancer with oral chemotherapy that works 2 ways

Sylvester Comprehensive Cancer Center researchers developed a first-of-its-kind orally administered drug Platin-L to disrupt prostate cancer cells' metabolism and deliver cisplatin directly into treatment-resistant cancer cells. The study showed that Platin-L is safe and effective in shrinking treatment-resistant cancers.

SourceUniversity of Miami Miller School of Medicine·JournalACS Central Science·DateJul 12, 2023

A new study published in NEJM Evidence with University Hospitals Seidman Cancer Center researchers and ArteraAI validates the first-ever predictive AI biomarker of androgen deprivation therapy (ADT) benefit in prostate cancer

A new study published in NEJM Evidence validates a predictive AI biomarker for androgen deprivation therapy (ADT) benefit in prostate cancer. The study found that personalized use of short-term ADT could improve patient outcomes in men with predominantly intermediate-risk prostate cancer.

SourceUniversity Hospitals Cleveland Medical Center·JournalNEJM Evidence·TypeData/statistical analysis·DateJun 30, 2023

A new generic treatment for multiple types of cancer

Researchers have developed a new technique to generically treat several kinds of cancer, showing tumors grew almost three times less and survival rates reached 100% after just one injection. The method targets cancer cells with alpha radiation, sparing healthy tissue.

SourceRIKEN·JournalChemical Science·DateJun 27, 2023

Metformin's role in preventing metabolic syndrome during androgen deprivation therapy: a Phase II study

A randomized phase II study found that adding metformin to androgen deprivation therapy did not reduce the risk of metabolic syndrome or improve PSA response in patients with advanced prostate cancer. Metformin showed some antitumor effects through mTOR inhibition, but these were not significant.

SourceImpact Journals LLC·JournalOncotarget·TypeRandomized controlled/clinical trial·DateJun 20, 2023

Addition of EBRT to brachytherapy did not improve outcomes for men with intermediate-risk prostate cancer, brachytherapy alone remains standard of care

The study found no improvement in freedom from progression rates for patients receiving combined EBRT and brachytherapy (COMBO) compared to those receiving brachytherapy alone (BT). Late adverse events were significantly increased in the COMBO arm, favoring BT as a standard of care for intermediate-risk prostate cancer patients.

SourceNRG Oncology·JournalJournal of Clinical Oncology·DateJun 15, 2023

A potential milestone in cancer therapy

A research team has identified a previously unknown weak spot in prostate cancer cells that could lead to new therapeutic approaches for other types of cancer. The study found that inhibiting this process can reduce cancer growth without affecting normal cell growth.

SourceUniversity of Connecticut·JournalMolecular Cell·TypeExperimental study·DateJun 8, 2023

American Indian and Alaska native men less likely to receive prostate cancer screening

A recent study found that American Indian and Alaska Native men are significantly less likely to receive prostate-specific antigen (PSA) testing and digital rectal exams from primary care providers compared to White men. This disparity results in poorer prostate cancer outcomes, particularly for men between 50-59 years old.

SourceAtrium Health Wake Forest Baptist·JournalCancer Causes & Control·DateJun 5, 2023

New study by Sylvester investigators indicates treatment patterns, not genetics, drive prostate cancer disparities

A large-scale retrospective analysis by Sylvester Comprehensive Cancer Center researchers found that differences in care, rather than genetics, likely explain disparities in advanced prostate cancer between men of African and European ancestries. Men of African ancestry are less likely to receive comprehensive genetic profiling and tar...

SourcePublic Relations Pacific LLC·JournalThe Lancet Digital Health·DateMay 24, 2023

The aging mouse prostate: kinetics of lymphocyte infiltration

Researchers tracked immune cell clusters in the aging mouse prostate using highly multiplexed immune profiling. Early adulthood sees myeloid cells, while between 6-12 months old, there's a profound shift to T and B lymphocyte-dominance. The study reveals new insight into prostatic inflammaging and the window for interventions.

SourceImpact Journals LLC·JournalAging-US·TypeComputational simulation/modeling·DateMay 23, 2023

ASCO: Targeted therapy for early breast cancer, progress treating recurrent glioma, PSMA PET scan advances and more

Researchers from the UCLA Jonsson Comprehensive Cancer Center are presenting findings on combination therapies for breast cancer and a potential new treatment for patients with recurrent glioma. A phase 3 study evaluating vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation is also be...

Prostate cancer ‘test by request’ policies drive overdiagnosis and inequity with minimal benefit, argue experts

Experts warn that shared decision-making policies for prostate cancer testing lead to high rates of unnecessary testing and harm, particularly in older men and those from disadvantaged areas. A comprehensive risk-based approach or restricting testing to symptomatic cases could reduce overdiagnosis and overtreatment.

SourceBMJ Group·JournalThe BMJ·TypeData/statistical analysis·DateMay 17, 2023